Rockville, Maryland, December 31, 2025
Samsung Biologics has announced the establishment of its first U.S. manufacturing facility in Rockville, Maryland, acquiring a site from GSK for $280 million. This investment is set to enhance drug manufacturing capabilities, support the local economy, and help create new job opportunities within the state’s growing life sciences sector. With over 500 jobs retained and more expected, this move reaffirms Maryland’s position in the biopharmaceutical landscape.
Samsung Biologics Chooses Rockville for U.S. Manufacturing Hub
New facility promises job creation and support for Maryland’s life sciences sector.
Rockville, Maryland – In a significant move for the local economy, Samsung Biologics has announced its plans to establish its first U.S. manufacturing facility in Rockville, Maryland. This strategic decision comes after fruitful discussions between Governor Wes Moore, the Maryland Department of Commerce, and executives from Samsung during an international trade mission to Asia. By acquiring an existing facility from GSK for $280 million, Samsung aims to enhance drug substance manufacturing capacity while modernizing its technology to meet growing global demand for medicines.
This development aligns with a broader pattern of international biopharmaceutical companies recognizing the advantages of Maryland’s life sciences sector. Samsung’s entry into Rockville not only promises to retain over 500 jobs but also anticipates new employment and business opportunities as the company integrates into the local landscape.
Rising Investments in Maryland’s Biopharmaceutical Sector
Maryland has seen a surge in investments from global biopharmaceutical companies, establishing itself as a hub for innovation and growth. Earlier in the year, Syngene International, an Indian pharmaceutical manufacturer, opened its first U.S. facility in Baltimore, generating 300 jobs. Concurrently, AstraZeneca committed a substantial $2 billion to enhance biologics manufacturing in Frederick County and build new clinical manufacturing space in Montgomery County. These investments are projected to create approximately 300 new jobs, alongside 1,900 construction jobs over the next four years.
The Value of Maryland’s Workforce and Research Institutions
The success in attracting these investments can be largely attributed to Maryland’s highly skilled workforce and prestigious research institutions. The state is home to over 500 biotech firms and boasts top-tier academic establishments like Johns Hopkins University and the University of Maryland. This ecosystem not only fosters innovation but also nurtures a collaborative environment that attracts investments and promotes economic growth.
Boosting the U.S. Medicines Supply Chain
The establishment of Samsung Biologics in Rockville is not just an economic boost for the local community; it also reinforces the resilience of the U.S. medicine supply chain. With an increasing need for transformative therapies, Maryland’s strategic positioning allows for accelerated access to essential medicines for patients both in America and globally.
Entrepreneurial Innovation and Small-Business Resilience
The growing presence of multinational corporations like Samsung Biologics, alongside smaller entities, illustrates the potential for entrepreneurial innovation in Maryland. Supporting policies and practices that facilitate business growth can further nurture an environment where both established companies and startups thrive. As we witness these investments, it is crucial to focus on the power of limited regulation to foster a climate of creativity and achievement.
Conclusion
The decision by Samsung Biologics to establish a manufacturing facility in Rockville heralds a positive trajectory for Maryland’s economy. The ripple effects of this investment are not only substantial for job creation but also for enhancing the overall competitiveness of the U.S. biopharmaceutical sector. Local leaders and residents alike can take pride in fostering an environment that supports innovation and growth. It is vital for the community to rally behind these developments and engage with local businesses to further bolster Baltimore’s economic future.
Frequently Asked Questions (FAQ)
What is the significance of Samsung Biologics establishing a manufacturing facility in Rockville, Maryland?
Samsung Biologics’ decision to set up its first U.S. manufacturing facility in Rockville underscores Maryland’s growing prominence in the global biopharmaceutical industry. The facility will expand drug substance manufacturing capacity and modernize technology to meet global demand for medicines. Over 500 jobs will be retained, with new employment opportunities and additional business planned as Samsung moves into its new Maryland space.
Which other international biopharmaceutical companies have invested in Maryland recently?
In addition to Samsung Biologics, Syngene International, an Indian pharmaceutical manufacturer, opened its first U.S. facility in Baltimore, creating 300 jobs. AstraZeneca committed $2 billion to expand its biologics manufacturing in Frederick County and build a new clinical manufacturing space in Montgomery County, generating approximately 300 new jobs and 1,900 construction jobs over the next four years.
What factors contribute to Maryland’s attractiveness for biopharmaceutical investments?
Maryland’s appeal lies in its highly skilled workforce, robust research institutions, and supportive business environment. The state’s life sciences sector includes over 500 biotech firms and is home to world-class academic institutions such as Johns Hopkins University and the University of Maryland.
Key Features of Maryland’s Biopharmaceutical Investments
| Company | Investment Details | Job Creation | Location |
|---|---|---|---|
| Samsung Biologics | First U.S. manufacturing facility in Rockville; acquired GSK’s site for $280 million; expanding drug substance manufacturing capacity and modernizing technology. | Over 500 jobs retained; new employment opportunities and additional business planned. | Rockville, Maryland |
| Syngene International | First U.S. facility in Baltimore; acquired biologics manufacturing site for $36.5 million; investing $13.5 million in renovations; adapting site for monoclonal antibody production. | 300 jobs created. | Baltimore, Maryland |
| AstraZeneca | $2 billion investment to expand biologics manufacturing in Frederick County and build new clinical manufacturing space in Montgomery County; enhancing U.S. medicines supply chain resilience. | Approximately 300 new jobs and 1,900 construction jobs over the next four years. | Frederick and Montgomery Counties, Maryland |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE BALTIMORE WRITER
The BALTIMORE STAFF WRITER represents the experienced team at HEREBaltimore.com, your go-to source for actionable local news and information in Baltimore, Baltimore County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Baltimore Book Festival, Preakness Stakes, and Artscape. Our coverage extends to key organizations like the Baltimore Chamber of Commerce and Visit Baltimore, plus leading businesses in shipping and healthcare that power the local economy such as the Port of Baltimore and Johns Hopkins Medicine. As part of the broader HERE network, we provide comprehensive, credible insights into Maryland's dynamic landscape.
